[1] |
中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J/OL]. 中华肝脏外科学术学电子,2024,13(4):407-449.DOI:10.3877/cma.j.issn.2095-3232.2024.04.001.Department of Medica Administration of National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer (2024 edition)[J/OL].Chin J Hepat Surg (Electronic Edition), 2024,13(4):407-449. DOI:10.3877/cma.j.issn.2095-3232.2024.04.001.
|
[2] |
Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma[J]. Hepatology, 2023, 78(6): 1922-1965. DOI: 10.1097/HEP.0000000000000466.
|
[3] |
European Association for the Study of the Liver. EASL clinical practice guidelines:management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1):182-236.DOI: 10.1016/j.jhep.2018.03.019.
|
[4] |
中国医疗保健国际交流促进会肝脏肿瘤学分会, 中国抗癌协会肝癌专业委员会, 中国医师协会肝癌专业委员会,等. 肝细胞癌新辅助及转化治疗中国专家共识 (2023版)[J].肝癌电子杂志,2023,10(4):1-14.
|
[5] |
He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. DOI: 10.1001/jamaoncol.2019.0250.
|
[6] |
Lyu N, Wang X, Li JB, et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1)[J].J Clin Oncol, 2022, 40(5): 468-480. DOI: 10.1200/JCO.21.01963.
|
[7] |
Zhao M, Guo Z, Zou YH, et al. Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations[J].Hepatol Int, 2024, 18(1): 4-31. DOI: 10.1007/s12072-023-10599-6.
|
[8] |
Rahbari NN, James Garden O, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS)[J]. Surgery, 2011, 149(5): 713-724.DOI: 10.1016/j.surg.2010.10.001.
|
[9] |
Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update[J]. Liver Cancer, 2021, 10(3): 181-223. DOI: 10.1159/000514174.
|
[10] |
Gan YX, Yang ZL, Pan YX, et al. Change of indocyanine green clearance ability and liver function after transcatheter intra-arterial therapies and its impact on outcomes of resectable hepatocellular carcinoma: a retrospective cohort study[J]. Int J Surg, 2024, 110(5):2832-2844. DOI: 10.1097/JS9.0000000000001156.
|
[11] |
Demirtas CO, D’Alessio A, Rimassa L, et al. ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma[J]. JHEP Rep, 2021, 3(5): 100347. DOI:10.1016/j.jhepr.2021.100347.
|
[12] |
詹一, 倪才方, 仲斌演, 等. ALBI分级在肝细胞癌肝功能评估及预后分层的应用及研究进展[J]. 实用医学杂志, 2023, 39(3): 381-385.DOI: 10.3969/j.issn.1006-5725.2023.03.021.Zhan Y, Ni CF, Zhong BY, et al. Research advances of ALBI grade for liver function assessment and prognosis stratification[J]. J Pract Med, 2023, 39(3): 381-385. DOI: 10.3969/j.issn.1006-5725.2023.03.021.
|
[13] |
蒋贝格, 周伟平. 肝切除术后肝衰竭早期诊断及预防[J/OL]. 中华肝脏外科手术学电子杂志, 2018, 7(5): 345-349. DOI: 10.3877/cma.j.issn.2095-3232.2018.05.001.
|
[14] |
Søreide JA, Deshpande R. Post hepatectomy liver failure (PHLF)-Recent advances in prevention and clinical management[J]. Eur J Surg Oncol, 2021, 47(2): 216-224. DOI: 10.1016/j.ejso.2020.09.001.
|
[15] |
Hoekstra LT, de Graaf W, Nibourg GAA, et al. Physiological and biochemical basis of clinical liver function tests: a review[J]. Ann Surg, 2013, 257(1): 27-36. DOI: 10.1097/SLA.0b013e31825d5d47.
|
[16] |
Granieri S, Bracchetti G, Kersik A, et al. Preoperative indocyanine green (ICG) clearance test: can we really trust it to predict post hepatectomy liver failure? A systematic review of the literature and meta-analysis of diagnostic test accuracy[J]. Photodiagnosis Photodyn Ther, 2022, 40: 103170. DOI: 10.1016/j.pdpdt.2022.103170.
|
[17] |
Pang Q, Zhou S, Liu S, et al. Prognostic role of preoperative albuminbilirubin score in posthepatectomy liver failure and mortality: a systematic review and meta-analysis[J]. Updates Surg, 2022, 74(3):821-831. DOI: 10.1007/s13304-021-01080-w.
|
[18] |
Marasco G, Alemanni LV, Colecchia A, et al. Prognostic value of the albumin-bilirubin grade for the prediction of post-hepatectomy liver failure: a systematic review and meta-analysis[J]. J Clin Med, 2021,10(9): 2011. DOI: 10.3390/jcm10092011.
|
[19] |
Wang LJ, Yan XL, Li J, et al. Indocyanine green clearance test for the preoperative assessment of chemotherapy-related hepatic injury in patients with colorectal liver metastasis[J]. Cancer Manag Res, 2020,12: 3237-3245. DOI: 10.2147/CMAR.S252693.
|
[20] |
Lin S, Song Z, Peng H, et al. A novel nomogram based on preoperative parameters to predict posthepatectomy liver failure in patients with hepatocellular carcinoma[J]. Surgery, 2023, 174(4): 865-873. DOI:10.1016/j.surg.2023.06.025.
|
[21] |
Wang JJ, Feng J, Gomes C, et al. Development and validation of prediction models and risk calculators for posthepatectomy liver failure and postoperative complications using a diverse international cohort of major hepatectomies[J]. Ann Surg, 2023, 278(6): 976-984.DOI: 10.1097/SLA.0000000000005916.
|
[22] |
Baumgartner R, Engstrand J, Rajala P, et al. Comparing the accuracy of prediction models to detect clinically relevant post-hepatectomy liver failure early after major hepatectomy[J]. Br J Surg, 2024,111(1): znad433. DOI: 10.1093/bjs/znad433.
|
[23] |
Seyama Y, Kokudo N. Assessment of liver function for safe hepatic resection[J]. Hepatol Res, 2009, 39(2): 107-116. DOI: 10.1111/j.1872-034X.2008.00441.x.
|
[24] |
Silva AS, Greensmith M, Praseedom RK, et al. Early derangement of INR predicts liver failure after liver resection for hepatocellular carcinoma[J]. Surgeon, 2022, 20(5): e288-e295. DOI: 10.1016/j.surge.2022.01.002.
|
[25] |
Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidencebased approach-the ALBI grade[J]. J Clin Oncol, 2015, 33(6): 550-558. DOI: 10.1200/JCO.2014.57.9151.
|
[26] |
Santol J, Kim S, Gregory LA, et al. An APRI+ALBI based multivariable model as preoperative predictor for posthepatectomy liver failure[J]. Ann Surg, 2023. DOI: 10.1097/SLA.0000000000006127.
|
[27] |
Zou H, Wen Y, Yuan K, et al. Combining albumin-bilirubin score with future liver remnant predicts post-hepatectomy liver failure in HBV-associated HCC patients[J]. Liver Int, 2018, 38(3): 494-502. DOI:10.1111/liv.13514.
|
[28] |
Wang YY, Xiang BD, Ma L, et al. Development and validation of a nomogram to preoperatively estimate post-hepatectomy liver dysfunction risk and long-term survival in patients with hepatocellular carcinoma[J]. Ann Surg, 2021, 274(6): e1209-e1217. DOI: 10.1097/SLA.0000000000003803.
|
[29] |
Deng M, Zhong C, Li D, et al. Hepatic arterial infusion chemotherapy-based conversion hepatectomy in responders versus nonresponders with hepatocellular carcinoma: a multicenter cohort study[J]. Int J Surg, 2024, 111(1): 135-145. DOI: 10.1097/JS9.0000000000002043.
|
[30] |
Berardi G, Morise Z, Sposito C, et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis[J]. J Hepatol, 2020, 72(1): 75-84. DOI:10.1016/j.jhep.2019.08.032.
|